Trials / Recruiting
RecruitingNCT06297525
Study of STP938 in Advanced Solid Tumours
An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Step Pharma, SAS · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STP938 | Small molecule |
Timeline
- Start date
- 2024-08-02
- Primary completion
- 2026-12-01
- Completion
- 2027-05-01
- First posted
- 2024-03-07
- Last updated
- 2025-04-15
Locations
7 sites across 3 countries: United States, France, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06297525. Inclusion in this directory is not an endorsement.